Budget Guide,Muscle

The field of targeted drug delivery has seen significant advancements, with researchers continually seeking novel strategies to enhance the efficacy of therapeutic agents. Among these innovations, the M12 muscle homing peptide has emerged as a promising tool, demonstrating a remarkable ability to specifically target and interact with muscle tissues. This peptide, identified through rigorous in vitro biopanning techniques, offers a unique advantage in delivering therapeutics directly to muscles, a critical factor in treating a wide range of conditions.

The core functionality of the M12 muscle homing peptide lies in its preferential binding to surface proteins found on muscle cells. This specific affinity allows it to act as a molecular beacon, guiding therapeutic payloads to their intended destination. Research has shown that the M12 peptide exhibits higher binding affinity to skeletal muscle compared to other organs like the liver, a crucial characteristic for minimizing off-target effects and maximizing therapeutic concentration at the site of action. This targeted approach is fundamental to improving outcomes in conditions affecting muscular health.

One of the most significant applications of the M12 muscle homing peptide is its role in enhancing the cellular uptake of various delivery systems, particularly nanoparticles (NPs). When covalently conjugated to carriers like PLGA-PEG NPs, the M12 peptide significantly boosts their entry into myoblasts, the precursor cells of muscle fibers. This enhanced cellular uptake is vital for delivering therapeutic agents, such as gene therapies or small molecules, directly into muscle cells, where they can exert their intended effects. Studies have explored the M12 peptide being covalently conjugated to PLGA-PEG NPs via the N-terminal α-amino groups of peptides using the N- linkage, a method that preserves the peptide's targeting capabilities.

The scientific literature highlights the efficacy of the M12 muscle homing peptide in preclinical models. For instance, its application in the context of Duchenne muscular dystrophy has shown considerable promise. In studies involving mdx mice, a common model for muscular dystrophy, the M12 peptide has been investigated for its ability to facilitate the delivery of antisense oligonucleotides, such as phosphorodiamidate morpholino oligomers (PMOs). This peptide-conjugate antisense based splice-correction strategy aims to restore dystrophin production, a protein deficient in individuals with Duchenne muscular dystrophy. Research by Gao et al. has provided evidence that a muscle-homing peptide alone can enhance AO delivery to muscle without appreciable toxicity at 75 mg/kg, underscoring the safety and effectiveness of this approach. Furthermore, PPMOs demonstrate effective exon skipping in target muscles and prolonged duration of dystrophin restoration after a treatment regime when conjugated with targeting peptides like M12.

Beyond gene therapy, the M12 muscle homing peptide is also being explored for its potential in delivering other therapeutic agents. For example, muscle homing peptide modified liposomes loaded with… are being investigated to improve drug delivery to skeletal muscles. The M12MNCs (Muscle Homing Peptide M12 Nanoparticles) have shown potential to improve age-related skeletal muscle dysfunction by modulating inflammation and cell proliferation, suggesting a broader therapeutic scope.

The characteristics of the M12 peptide make it a valuable asset in the development of advanced drug delivery systems. It is described as a novel 12-mer peptide with a specific chemical composition, indicated by its PubChem CID 172638599 and chemical formula C59H100N24O17. The molar mass (M) of 1416.8 g/mol is a key parameter for formulation and dosage calculations. For researchers and biopharmaceutical companies looking to utilize this peptide, M12 muscle-homing peptide CRB1001635 can be bought online for pharmaceutical testing and as high-quality reference standards. Available quantities include 500 µg per Pack and 1 mg per Pack, with specific Art. No. 2AX2.1 and 2AX2.2 respectively. The recommended storage temperature is -20 °C, with transport at ambient temperature.

The broader category of homing peptides encompasses molecules with similar targeting capabilities, and the M12 muscle homing peptide stands out due to its specific tropism for muscle tissue. While other homing peptides might target different tissues, such as tumor-homing peptides like RGD and NGR, the M12 peptide's unique ability to preferentially bind to skeletal muscle makes it indispensable for muscle-related research and therapeutic development. This peptide's capacity to favor cellular uptake/localization within muscle-related settings when linked into an appropriate carrier context is a testament to its targeted functionality.

In summary, the M12 muscle homing peptide represents a significant stride in targeted therapeutics. Its ability to specifically bind to muscle tissues, enhance cellular uptake of nanoparticles, and facilitate the delivery of therapeutic agents like PMOs makes it a critical component for addressing **